---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018526"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:07:25.245683+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytoDyn shareholders approve authorized common stock increase to 1.75B shares

## Summary
- Authorized shares increased from 1.35B to 1.75B, approved by 504.7M for vs 42.6M against.
- All five director nominees elected: Tanya Durkee Urbach, Stephen Simes, Ryan Dunlap, Lishomwa Ndhlovu, Karen Brunke.
- Advisory vote on named executive officer compensation passed with 297.5M for, 63.6M against, 14.2M abstentions.
- Share increase effective immediately upon filing Certificate of Amendment with Delaware Secretary of State on Nov 9, 2023.

## SEC filing metadata
- accession: 0001558370-23-018526
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837023018526/0001558370-23-018526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837023018526/cydy-20231109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018526
- JSON: https://secwatch.observer/filing/0001558370-23-018526.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018526.txt

## Key facts
- Governance Changes
  CytoDyn Inc.: Increased authorized shares of common stock from 1,350,000,000 to 1,750,000,000 (effective 2023-11-09).
  - Change: charter amendment
  - Effective: 2023-11-09
  source text: On November 9, 2023, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation, increasing the total number of authorized shares of common stock, par value $0.001 per share, from 1,350,000,000 to 1,750,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023018526/0001558370-23-018526-index.htm
- Shareholder Votes
  CytoDyn Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-11-09 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-11-09
  source text: The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023018526/0001558370-23-018526-index.htm
- Shareholder Votes
  CytoDyn Inc. shareholders approved Vote to amend the Company’s certificate of incorporation to increase the total number of authorized shares of common stock from 1,350,000,000 to 1,750,000,000 shares at the 2023-11-09 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-11-09
  source text: The stockholders approved an amendment to the Company’s certificate of incorporation to increase the total number of authorized shares of common stock from 1,350,000,000 to 1,750,000,000 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023018526/0001558370-23-018526-index.htm
- Shareholder Votes
  CytoDyn Inc. shareholders approved Election of Directors at the 2023-11-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-11-09
  source text: The stockholders elected each of the Company’s director nominees to serve until the Company’s 2024 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023018526/0001558370-23-018526-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.